Script Macromedia Flash
 

Pesquisa

Topo 1
Topo 2

In Utero Antidepressants and Neurodevelopmental Outcomes in Kindergarteners

Deepa Singal, PhD, Dan Chateau, PhD, Shannon Struck et al. Pediatrics Volume 145, number 5, May:e20191157

Abstract

OBJECTIVES: To determine if in utero selective serotonin reuptake inhibitor (SSRI) or selective abstract serotonin norepinephrine inhibitor (SNRI) exposure is associated with developmental vulnerability in kindergarten among children whose mothers were diagnosed with prenatal mood or anxiety disorder.

 
METHODS: Linkable administrative data were used to create a population-based cohort of 266 479 mother-child dyads of children born in Manitoba, Canada, between 1996 and 2014, with follow-up through 2015. The sample was restricted to mothers who had a mood or anxiety disorder diagnosis between 90 days before conception (N = 13 818). Exposed women had $2 SSRI or SNRI dispensations during pregnancy (n = 2055); unexposed mothers did not have a dispensation of an SSRI or SNRI during pregnancy (n = 10 017). The Early Development Instrument (EDI) was used to assess developmental health in kindergarten children.
The EDI is a 104-component kindergarten teacher-administered questionnaire, encompassin developmental domains.
 
RESULTS: Of the 3048 children included in the study who met inclusion criteria and had an EDI, 21.43% of children in the exposed group were assessed as vulnerable on 2 or more domains versus 16.16% of children in the unexposed group (adjusted odds ratio = 1.43; 95% confidence interval 1.08–1.90). Children in the exposed group also had a significant risk of being vulnerable in language and/or cognition (adjusted odds ratio = 1.40; 95% confidence interval 1.03–1.90).
 
CONCLUSIONS: Exposure to SSRIs or SNRIs during pregnancy was associated with an increased risk of developmental vulnerability and an increased risk of deficits in language and/or cognition. Replication of results is necessary before clinical implications can be reached.
 
VER PDF  (1655Kb)
Voltar